
- With Mayo Clinic gynecologist and obstetrician
Mary M. Gallenberg, M.D.
read biographyclose windowBiography of
Mary M. Gallenberg, M.D.
Mary M. Gallenberg, M.D.
Dr. Mary Gallenberg is board certified by the American Board of Obstetrics and Gynecology and by the American Board of Internal Medicine in internal medicine and medical oncology.
An Antigo, Wis., native, Dr. Gallenberg is a consultant in the Department of Obstetrics & Gynecology at Mayo Clinic, Rochester, Minn., and an assistant professor at College of Medicine, Mayo Clinic.
Dr. Gallenberg has been with Mayo Clinic since 1990. She was on the Mayo Clinic Women's HealthSource editorial board and has been honored for excellence in teaching. She also won a Mayo Clinic Excellence Through Teamwork award.
Risk factors (1)
- Ovarian cancer: Still possible after hysterectomy?
Symptoms (1)
- CA 125 test: A screening test for ovarian cancer?
Tests and diagnosis (1)
- Pap smear: Can it detect ovarian cancer?
Prevention (1)
- Ovarian cancer vaccine: Can it prevent recurrence?
Question
CA 125 test: A screening test for ovarian cancer?
Should I ask my doctor for a CA 125 blood test to screen for ovarian cancer?
Answer
from Mary M. Gallenberg, M.D.
The cancer antigen 125 (CA 125) blood test isn't recommended for women with an average risk of ovarian cancer.
While women with ovarian cancer often have an elevated level of CA 125, an elevated CA 125 level doesn't always mean you have ovarian cancer. Some women with ovarian cancer never have an elevated CA 125 level.
Many other conditions also can cause an elevated CA 125 level, including:
- Diverticulitis
- Endometriosis
- Liver cirrhosis
- Normal menstruation
- Pregnancy
- Uterine fibroids
For these reasons, doctors don't recommend CA 125 testing in women with an average risk of ovarian cancer.
Women with a high risk of ovarian cancer, such as those with mutations in the BRCA1 and BRCA2 genes, which increase the risk of breast and ovarian cancers, may consider periodic CA 125 testing. But even in these high-risk situations, there's some disagreement about the usefulness of the CA 125 test.
A study of 78,216 women ages 55 to 74 randomly selected to receive either an annual CA 125 test and pelvic ultrasound screening or the usual medical care showed that CA 125 test and ultrasound screening did not reduce ovarian cancer deaths. The study also found that false-positive tests resulted in serious complications.
If you're concerned about your risk of ovarian cancer, ask your doctor about your screening options and ways to reduce your risk.
Next questionPap smear: Can it detect ovarian cancer?
- Nossov V, et al. The early detection of ovarian cancer: From traditional methods to proteomics. Can we really do better than serum CA-125? American Journal of Obstetrics & Gynecology. 2008;199:215.
- Screening for ovarian cancer. U.S. Preventive Services Task Force. http://www.uspreventiveservicestaskforce.org/3rduspstf/ovariancan/ovcanrs.pdf. Accessed Aug. 10, 2011.
- Buys SS, et al. Effect of screening on ovarian cancer mortality: The prostate, lung, colorectal and ovarian (PLCO) cancer screening randomized controlled trial. Journal of the American Medical Association. 2011;305:2295.

Find Mayo Clinic on